Evidence map›Paper›PMID 31259888›Full record

ArticleJournal of visualized experiments : JoVE2019

Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer.

Kristine M Wadosky, Yanqing Wang, Xiaojing Zhang, David W Goodrich

Open access · greenAbstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Organoid of ovarian cancer: genomic analysis and drug screening.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kristine M WadoskyDepartment of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center; kristine.wadosky@roswellpark.org.
Yanqing WangDepartment of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center.
Xiaojing ZhangDepartment of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center.
David W GoodrichDepartment of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center.
Roswell Park Comprehensive Cancer Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6M
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancerR01CA234162 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI GOODRICH, DAVID W. · 2019 to 2024
$3.0M
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancerR01CA207757 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI ELLIS, LEIGH, GOODRICH, DAVID W. · 2016 to 2020
$2.8M
(PQB5) Does the timing of Pten and Rb1 mutation affect prostate cancer phenotypesR21CA179907 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI GOODRICH, DAVID W. · 2013 to 2014
$401k
NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA207757NCI NIH HHS R01 CA234162NCI NIH HHS R21 CA179907
6 · The paper itself

Abstract

Methods based on homologous recombination to modify genes have significantly furthered biological research. Genetically engineered mouse models (GEMMs) are a rigorous method for studying mammalian development and disease. Our laboratory has developed several GEMMs of prostate cancer (PCa) that lack expression of one or multiple tumor suppressor genes using the site-specific Cre-loxP recombinase system and a prostate-specific promoter. In this article, we describe our method for necropsy of these PCa GEMMs, primarily focusing on dissection of mouse prostate tumors. New methods developed over the last decade have facilitated the culture of epithelial-derived cells to model organ systems in vitro in three dimensions. We also detail a 3D cell culture method to generate tumor organoids from mouse PCa GEMMs. Pre-clinical cancer research has been dominated by 2D cell culture and cell line-derived or patient-derived xenograft models. These methods lack tumor microenvironment, a limitation of using these techniques in pre-clinical studies. GEMMs are more physiologically-relevant for understanding tumorigenesis and cancer progression. Tumor organoid culture is an in vitro model system that recapitulates tumor architecture and cell lineage characteristics. In addition, 3D cell culture methods allow for growth of normal cells for comparison to tumor cell cultures, rarely possible using 2D cell culture techniques. In combination, use of GEMMs and 3D cell culture in pre-clinical studies has the potential to improve our understanding of cancer biology.

Indexed as

AnimalsCell Culture TechniquesDisease Models, AnimalGenetic EngineeringMaleMiceOrganoidsProstatic NeoplasmsTumor Microenvironment

Identifiers

PMID31259888
PMCPMC9014379
OpenAlexW2949124845

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.